Esperion Therapeutics (NASDAQ:ESPR) Sees Strong Trading Volume – Here’s What Happened

Esperion Therapeutics, Inc. (NASDAQ:ESPR) shares saw an uptick in trading volume on Monday . 8,005,833 shares were traded during mid-day trading, an increase of 3% from the previous session’s volume of 7,745,387 shares.The stock last traded at $3.1150 and had previously closed at $3.11.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on ESPR. Jefferies Financial Group lowered Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 1st. Citizens Jmp lowered Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 1st. HC Wainwright downgraded Esperion Therapeutics from a “buy” rating to a “neutral” rating and set a $3.16 price objective on the stock. in a report on Friday, May 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Esperion Therapeutics in a report on Tuesday, April 21st. Finally, Piper Sandler downgraded Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, May 1st. One analyst has rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Esperion Therapeutics presently has an average rating of “Hold” and a consensus target price of $5.54.

Esperion Therapeutics Trading Up 1.0%

The company has a fifty day simple moving average of $2.54 and a two-hundred day simple moving average of $3.09. The company has a market cap of $810.81 million, a PE ratio of -18.53, a P/E/G ratio of 2.53 and a beta of 0.91.

Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings results on Tuesday, March 10th. The biopharmaceutical company reported $0.22 earnings per share for the quarter, missing the consensus estimate of $0.23 by ($0.01). The business had revenue of $168.45 million during the quarter, compared to the consensus estimate of $165.12 million. On average, research analysts anticipate that Esperion Therapeutics, Inc. will post 0.05 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Bank of New York Mellon Corp increased its holdings in shares of Esperion Therapeutics by 1.1% in the 1st quarter. Bank of New York Mellon Corp now owns 555,177 shares of the biopharmaceutical company’s stock valued at $1,521,000 after acquiring an additional 6,083 shares during the last quarter. Summit Wealth Group LLC grew its stake in Esperion Therapeutics by 19.0% during the 1st quarter. Summit Wealth Group LLC now owns 405,369 shares of the biopharmaceutical company’s stock worth $1,111,000 after buying an additional 64,763 shares during the last quarter. Principal Financial Group Inc. grew its stake in Esperion Therapeutics by 53.0% during the 1st quarter. Principal Financial Group Inc. now owns 422,776 shares of the biopharmaceutical company’s stock worth $1,158,000 after buying an additional 146,484 shares during the last quarter. Hsbc Holdings PLC grew its stake in Esperion Therapeutics by 160.1% during the 1st quarter. Hsbc Holdings PLC now owns 48,141 shares of the biopharmaceutical company’s stock worth $132,000 after buying an additional 29,631 shares during the last quarter. Finally, AIGH Capital Management LLC grew its stake in Esperion Therapeutics by 10.0% during the 1st quarter. AIGH Capital Management LLC now owns 4,400,000 shares of the biopharmaceutical company’s stock worth $12,056,000 after buying an additional 400,000 shares during the last quarter. Hedge funds and other institutional investors own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.